Connor, Clark & Lunn Investment Management (CC&L)’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-129,710
| Closed | -$3.64M | – | 1752 |
|
|
2026
Q1 | $3.64M | Buy |
+129,710
| New | +$3.45M | 0.01% | 786 |
|
|
2024
Q4 | – | Sell |
-14,801
| Closed | -$428K | – | 1585 |
|
|
2024
Q3 | $428K | Buy |
14,801
+5,959
| +67% | +$174K | ﹤0.01% | 1137 |
|
|
2024
Q2 | $247K | Sell |
8,842
-347,911
| -98% | -$9.58M | ﹤0.01% | 1227 |
|
|
2024
Q1 | $9.9M | Sell |
356,753
-120,868
| -25% | -$3.35M | 0.04% | 297 |
|
|
2023
Q4 | $13.8M | Sell |
477,621
-1,564,632
| -77% | -$47.3M | 0.06% | 235 |
|
|
2023
Q3 | $67.7M | Buy |
2,042,253
+271,052
| +15% | +$9.59M | 0.35% | 59 |
|
|
2023
Q2 | $65M | Buy |
1,771,201
+83,419
| +5% | +$3.25M | 0.32% | 68 |
|
|
2023
Q1 | $68.9M | Buy |
1,687,782
+390,628
| +30% | +$16.9M | 0.37% | 58 |
|
|
2022
Q4 | $66.5M | Buy |
+1,297,154
| New | +$62.2M | 0.38% | 51 |
|
|
2022
Q3 | – | Sell |
-114,139
| Closed | -$5.98M | – | 1217 |
|
|
2022
Q2 | $5.98M | Sell |
114,139
-29,125
| -20% | -$1.48M | 0.04% | 278 |
|
|
2022
Q1 | $7.42M | Sell |
143,264
-552,661
| -79% | -$28.7M | 0.04% | 261 |
|
|
2021
Q4 | $41.1M | Sell |
695,925
-1,622,491
| -70% | -$80.4M | 0.2% | 95 |
|
|
2021
Q3 | $99.7M | Buy |
2,318,416
+656,422
| +39% | +$29.1M | 0.52% | 40 |
|
|
2021
Q2 | $65.1M | Buy |
1,661,994
+519,351
| +45% | +$20.2M | 0.33% | 65 |
|
|
2021
Q1 | $41.4M | Buy |
1,142,643
+618,619
| +118% | +$22M | 0.23% | 93 |
|
|
2020
Q4 | $19.3M | Sell |
524,024
-592,782
| -53% | -$21.7M | 0.11% | 145 |
|
|
2020
Q3 | $38.9M | Buy |
1,116,806
+852,863
| +323% | +$29.9M | 0.26% | 78 |
|
|
2020
Q2 | $8.19M | Sell |
263,943
-464,367
| -64% | -$15.8M | 0.06% | 227 |
|
|
2020
Q1 | $22.6M | Buy |
728,310
+95,667
| +15% | +$3.26M | 0.2% | 96 |
|
|
2019
Q4 | $23.5M | Sell |
632,643
-1,307,964
| -67% | -$46.6M | 0.16% | 109 |
|
|
2019
Q3 | $66.2M | Buy |
1,940,607
+1,538,840
| +383% | +$56M | 0.45% | 44 |
|
|
2019
Q2 | $16.5M | Sell |
401,767
-333,666
| -45% | -$13.2M | 0.11% | 142 |
|
|
2019
Q1 | $29.6M | Buy |
735,433
+76,121
| +12% | +$3.05M | 0.2% | 95 |
|
|
2018
Q4 | $27.3M | Buy |
659,312
+70,154
| +12% | +$2.91M | 0.19% | 95 |
|
|
2018
Q3 | $24.6M | Sell |
589,158
-494,457
| -46% | -$19M | 0.14% | 120 |
|
|
2018
Q2 | $37.3M | Sell |
1,083,615
-303,094
| -22% | -$10.4M | 0.21% | 83 |
|
|
2018
Q1 | $46.7M | Buy |
1,386,709
+285,002
| +26% | +$9.8M | 0.28% | 71 |
|
|
2017
Q4 | $37.9M | Sell |
1,101,707
-131,183
| -11% | -$4.47M | 0.22% | 86 |
|
|
2017
Q3 | $41.8M | Buy |
1,232,890
+373,169
| +43% | +$12M | 0.25% | 74 |
|
|
2017
Q2 | $27.4M | Sell |
859,721
-81,298
| -9% | -$2.56M | 0.18% | 97 |
|
|
2017
Q1 | $30.5M | Sell |
941,019
-201,656
| -18% | -$6.36M | 0.2% | 89 |
|
|
2016
Q4 | $35.2M | Sell |
1,142,675
-294,363
| -20% | -$8.99M | 0.24% | 68 |
|
|
2016
Q3 | $46.2M | Buy |
1,437,038
+125,215
| +10% | +$4.19M | 0.32% | 53 |
|
|
2016
Q2 | $43.8M | Sell |
1,311,823
-413,669
| -24% | -$13.2M | 0.32% | 58 |
|
|
2016
Q1 | $48.5M | Buy |
1,725,492
+163,449
| +10% | +$4.67M | 0.38% | 44 |
|
|
2015
Q4 | $47.8M | Sell |
1,562,043
-55,335
| -3% | -$1.74M | 0.4% | 43 |
|
|
2015
Q3 | $48.2M | Buy |
1,617,378
+1,085,737
| +204% | +$34.8M | 0.39% | 45 |
|
|
2015
Q2 | $16.9M | Buy |
531,641
+264,923
| +99% | +$8.63M | 0.15% | 84 |
|
|
2015
Q1 | $8.8M | Buy |
266,718
+5,270
| +2% | +$168K | 0.07% | 123 |
|
|
2014
Q4 | $7.73M | Sell |
261,448
-804,096
| -75% | -$23.1M | 0.06% | 125 |
|
|
2014
Q3 | $29.9M | Sell |
1,065,544
-588,027
| -36% | -$16.5M | 0.24% | 58 |
|
|
2014
Q2 | $49.6M | Buy |
1,653,571
+777,325
| +89% | +$22.2M | 0.35% | 51 |
|
|
2014
Q1 | $29.5M | Sell |
876,246
-93,595
| -10% | -$2.79M | 0.22% | 67 |
|
|
2013
Q4 | $29.9M | Buy |
969,841
+556,617
| +135% | +$16.2M | 0.23% | 57 |
|
|
2013
Q3 | $11.6M | Buy |
413,224
+18,761
| +5% | +$510K | 0.1% | 73 |
|
|
2013
Q2 | $11.1M | Buy |
+394,463
| New | +$10.9M | 0.11% | 74 |
|
Other funds holding PFE
Connor, Clark & Lunn Investment Management (CC&L)'s PFE Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) sold out of Pfizer (PFE) in Q2 2026, closing a stake of 129,710 shares — an estimated $3.64M sold.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PFE in Q2 2013 and held it in 46 quarters. The position peaked at $99.7M in Q3 2021. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- Connor, Clark & Lunn Investment Management (CC&L) sold 129,710 Pfizer shares in Q2 2026, an estimated $3.64M.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Pfizer in Q2 2013 and held it in 46 quarters.
- Connor, Clark & Lunn Investment Management (CC&L)'s Pfizer position peaked at $99.7M in Q3 2021.
- 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.